PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12801846-8	2003	With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed.	Enoxaparin	74-84	coagulation factor III, tissue factor	Homo sapiens	109-111	
19703818-5	2009	In addition, sulodexide had a stronger inhibitory effect on TF-mediated microparticle generation (IC(50) = 2.8 microg/ mL), P-selectin expression (IC(50) = 4.8 microg/ml), and platelet aggregate formation (IC(50) = 8.5 microg/mL) compared to higher IC(50) values with enoxaparin.	Enoxaparin	268-278	coagulation factor III, tissue factor	Homo sapiens	60-62	
11323025-5	2001	At 0.01 U/ml, enoxaparin exhibited a stronger inhibition of TF-induced platelet activation compared to ardeparin and dalteparin.	Enoxaparin	14-24	coagulation factor III, tissue factor	Homo sapiens	60-62	
11323025-12	2001	Thus, at therapeutic concentrations (0.8-1.2 U/ml), enoxaparin itself was capable of inhibiting TF-mediated activation of platelets to > 70%; whereas tirofiban failed to produce such concentration-dependent inhibition.	Enoxaparin	52-62	coagulation factor III, tissue factor	Homo sapiens	96-98